Pharmacoeconomic studies in Italy: A critical review of the literature

European Journal of Health Economics

Volumn 8, Issue 2, 2007, Pages 89-95

  Cornago, D ^a   Li Bassi, L ^a   De Compadri, P ^a   Garattini, L ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Italy; Pharmacoeconomics; Review

Indexed keywords

COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH ECONOMICS; HUMAN; ITALY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; SENSITIVITY ANALYSIS;

ECONOMICS, PHARMACEUTICAL; HUMANS; ITALY;

EID: 34248363650     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0011-8     Document Type: Review

References (30)

1. Drummond, M.F., Brown, R., Fendrick, A.M., et al.: Use of pharmacoeconomics information report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 6(4), 407-416 (2003)
2. Drummond, M.F. Jönsson, B., Rutten, H.F.F.: The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40, 199-215 (1997)
3. Henry, D., Lang, D.: Published pharmacoeconomic analyses: science or marketing? Intern. Med. J. 33(9-10), 403-404 (2003)
4. Drummond, M.F.: Economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics 1(1), 8-13 (1992)
5. Drummond, M.F., Cooke, J., Walley, T.: Economic evaluation under managed competition: evidence from the U.K. Soc. Sci. Med. 45(4), 583-595 (1997)
6. Drummond, M.F.: A reappraisal of economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics 14(1), 1-9 (1998)
7. Hill, S.R., Mitchell, A.S., Henry, D.A.: Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian pharmaceutical benefits scheme. JAMA 283(16), 2116-2121 (2000)
8. Laupacis, A.: Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they right ones? Can. Med. Ass. J. 166, 44-47 (2002)
9. Hoffmann, C., Graf von der Schulemburg, J.M.: The influence of economic evaluation studies on decision making. A European survey. The EUROMET group. Health Policy 52(3), 179-192 (2000)
10. Ijzerman, M.J., Reuzel, R.P., Severens, H.L.: Pre-assessment to assess the match between cost-effectiveness results and decision makers' information needs: an illustration using two cases in rehabilitation medicine in The Netherlands. Int. J. Technol. Assess. 19(1), 17-27 (2003)
11. Hoffman, C., Stoykova, B.A., Nixon, J., et al.: Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health 5(2), 71-78 (2002)
12. Spath, H.M., Charavel, M., Morelle, M., Carrère, M.O.: Formulary decision-making in public hospitals and private clinics in France: the role of pharmacoeconomic information. J. Econ. Med. 22(7-8), 347-354 (2004)
13. France, G., Taroni, F.: The evolution of health-policy making in Italy. J. Health Polit. Policy Law 30(1-2), 169-87 (2005)
14. Drummond, M.F., Dubois, D., Garattini, L., et al.: Current trends in the use of pharmacoeconomics and outcomes research in Europe. ValueHealth 2(5), 323-332 (1999)
15. Garattini, L., De Compadri, P., Clemente, R., Cornago, D.: Economic evaluations in Italy: a review of the literature. Int. J. Technol. Assess. 19(4), 685-737 (2003)
16. De Pouvourville, G., Ulmann, P., Nixon, J., et al.: The diffusion of health economics knowledge in Europe. The EURONHEED (European network of health economic evaluation databases) project. Pharmacoeconomics 23(2), 113-120 (2005)
17. Buxton, M.J., Drummond, M.F., Van Hout, B.A., et al.: Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6(3), 217-227 (1997)
18. Drummond, M.F., Davis, L.: Economic analysis alongside clinical trials: revisiting the methodological issues. Int. J. Technol. Assess. 7(4), 561-573 (1991)
19. Garattini, L., Grilli, R., Scopelliti, D., et al.: A proposal for Italian guidelines in pharmacoeconomics. PharmacoEconomics 7(1), 1-6 (1995)
20. Taroni F.: DRG/SDO e Nuovo Sistema di Finanziamento Degli Ospedali. Il Pensiero Scientifico Editore, Roma (1996)
21. Rabeneck, L., Viscoli, C.M., Horwitz, R.I.: Problems in the conduct and analysis of randomized clinical trias. Are we getting the right answers to the wrong questions? Arc. Intern. Med. 152(3), 507-512 (1992)
22. Sacks, H.S., Terrier, J., Reitmann, D., Ancona-Berck, V.A., Chalmers, T.C.: Meta-analyses of randomized controlled trials. N. Engl. J. Med. 316(8), 450-455 (1987)
23. Egger, M., Smith, G.D., Phillips, A.N.: Meta-analysis. Princ. proced. BMJ 315, 1533-1537 (1997)
24. Smith, G.D., Phillips, A.N.: Meta-analysis. Beyond the grand mean? BMJ 315, 1610-1614 (1997)
25. Crombie, I.K.: The Pocket Guide to Critical Appraisal. BMJ Publishing group, London(1996)
26. Drummond, M.F., O'Brien, B, Stoddart, G.L., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications, Oxford (1997)
27. Krimsky, S.: Conflict of interest and cost-effectiveness analysis. JAMA 282(15), 1474-1475 (1999)
28. Morgan, S., Barer, M., Evans, R.: Health economists meet the fourth tempter: drug dependency and scientific discorse. Health Econ. 9, 659-667 (2000)
29. Rennie, D., Luft, H.: Pharmacoeconomic analysis: making them transparent, making them credible. JAMA 283(16), 2158-2160 (2000)
30. De Compadri, P., Cornago, D., Garattini, L.: The Influence of Economic Evaluations Studies on Decision-Making in Italy. In: Eberhardt, S., Stoklossa, C., Graf von der Schulenburg, J.M.: (eds) EUROMET 2004: The Influence of Economic Evaluations on Decision Making. IOS Press, Amsterdam (2005)